Group 1 - The company plans to globally offer 27.72 million shares, with 2.77 million shares available in Hong Kong and 24.95 million shares for international offering, along with an over-allotment option of 4.16 million shares [1] - The subscription period for the shares is set from December 30, 2025, to January 5, 2026, with a maximum offer price of HKD 43.24 per share and an entry fee of approximately HKD 4,367.61 for a board lot of 100 shares [1] - The total expected fundraising amount is HKD 1.199 billion, with a net amount of HKD 1.117 billion, which will be allocated for ongoing and planned R&D of core products, commercialization of core products, working capital, capacity expansion, potential strategic acquisitions or investments in the surgical robotics industry, and other products under development [1] Group 2 - The company is expected to be listed on the main board on January 8, 2026, with Morgan Stanley Asia Limited and GF Securities (Hong Kong) Limited acting as joint sponsors [2] - The company's main business includes economic information consulting, software development, import and export of electronic devices and medical equipment, and R&D, production, and sales of smart devices, medical robots, and related equipment [2] - The company's net profits for the fiscal years 2023, 2024, and the first half of 2025 (ending June 30) are projected to be -213 million, -219 million, and -89.09 million respectively [2]
精锋医疗-B(02675.HK)拟全球发售2772.22万股 12月30日起招股